Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Perspective Therapeutics ( (CATX) ) has provided an announcement.
Perspective Therapeutics reported first-quarter 2026 results on May 11, 2026, highlighting progress across three clinical-stage oncology programs—VMT-α-NET for neuroendocrine tumors, VMT01 for melanoma and PSV359 for FAP-positive solid tumors—alongside expansion of its preclinical pipeline with new 212Pb-based constructs such as PSV594. The company detailed ongoing dose-finding studies with multiple cohorts fully enrolled or open for recruitment, presented interim clinical data at a major cancer meeting, and underscored potential expedited paths in high unmet-need indications like meningioma.
Operationally, Perspective is advancing construction of its Chicago manufacturing site, building a complementary Los Angeles facility and planning further capacity, positioning its infrastructure to support reliable supply of ready-to-administer radiopharmaceuticals. Financially, the company strengthened its balance sheet via a February 2026 equity offering that lifted cash, cash equivalents and short-term investments to about $271 million as of March 31, 2026, extending its expected cash runway into late 2027 despite higher research and development spending and a widened quarterly net loss driven by increased clinical and manufacturing investments.
The most recent analyst rating on (CATX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Perspective Therapeutics stock, see the CATX Stock Forecast page.
Spark’s Take on CATX Stock
According to Spark, TipRanks’ AI Analyst, CATX is a Neutral.
The score is held down primarily by weak financial performance (no current revenue, widening losses, and accelerating cash burn). Technicals also point to a bearish trend despite oversold readings. Positive corporate events—encouraging interim clinical updates and funding runway into late 2027—partly offset these risks but do not outweigh the current fundamental deterioration.
To see Spark’s full report on CATX stock, click here.
More about Perspective Therapeutics
Perspective Therapeutics, Inc. is a radiopharmaceutical development company focused on advanced cancer treatments using proprietary technology built around the alpha-emitting isotope 212Pb. The company pairs targeted radiotherapies with complementary imaging in a theranostic model to personalize treatment, and is building a regional manufacturing network, including flagship facilities in Chicago and Los Angeles, to support clinical and potential commercial supply.
Average Trading Volume: 1,591,810
Technical Sentiment Signal: Sell
Current Market Cap: $428.7M
See more insights into CATX stock on TipRanks’ Stock Analysis page.